Life Sciences BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL AIT News Desk Jun 13, 2022 Following Additional Data Submission to FDA Demonstrating ORR Superiority Over Ibrutinib As Determined by IRC, PDUFA Goal Date Extended to…
Life Sciences BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European… AIT News Desk Jun 10, 2022 BeiGene , a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and…